natgillin/translations-raw huggingface dataset:
Administration procedures should be carried out in a way to minimize risk of contamination of the medicinal product and irradiation of the operators. 
Postopke dajanja je treba izvajati tako, da se čim bolj zmanjša tveganje za kontaminacijo zdravila in obsevanje osebja.
Duration of the procedure Your nuclear medicine doctor will inform you about the usual duration of the procedure. 
Zdravnik nuklearne medicine vas bo seznanil z običajnim časom za izvedbo postopka.
SomaKit TOC is supplied as a kit containing two vials. 
Zdravilo SomaKit TOC je dobavljeno v kompletu, ki vsebuje dve viali.
If you have been given more SomaKit TOC than you should An overdose is unlikely because you will only receive a single dose under controlled conditions by the nuclear medicine doctor supervising the procedure. 
Preveliko odmerjanje ni verjetno, saj boste prejeli le en odmerek zdravila pod nadzorovanimi pogoji s strani zdravnika nuklearne medicine, ki bo nadzoroval postopek.
An increased uptake of gallium (68Ga) edotreotide is not specific for GEP-NET. 
Povečan privzem [68Ga]galij-edotreotida ni specifičen za GEP NET.
Gallium (68Ga) edotreotide solution is stable up to 4 hours after preparation. 
Raztopina [68Ga]galij-edotreotida je stabilna 4 ure po pripravi.
Radiopharmaceuticals should be received, used and administered only by authorized persons in designated clinical settings. 
Radiofarmake sme sprejemati, uporabljati in dajati samo pooblaščeno osebje v pooblaščenih zdravstvenih ustanovah.
At the time of administration, the product must be aseptically withdrawn and the radioprotection standards must be followed. 
V času dajanja je treba zdravilo izvleči na aseptičen način in pri tem upoštevati standarde za zaščito pred sevanjem.
- The other ingredients are: 1,10-phenanthroline, gentisic acid, mannitol, formic acid, sodium hydroxide, water for injections. 
- pomožne snovi so: 1,10-fenantrolin, gentizinska kislina, manitol, mravljinčna kislina, natrijev hidroksid, voda za injekcije.
SomaKit TOC contains sodium (see section 2). 
Zdravilo SomaKit TOC vsebuje natrij (glejte poglavje 2).
Use waterproof gloves, effective radiation shielding, and appropriate safety measures when handling the radiolabelled SomaKit TOC to avoid unnecessary radiation exposure to the patient, occupational workers, clinical personnel, and other persons. 
učinkovito zaščito pred sevanjem in ustrezne varnostne ukrepe, da preprečite nepotrebno izpostavljenost bolnika, delavcev, kliničnega osebja in drugih oseb sevanju.
Add the reaction buffer previously dosed in the 1 ml sterile syringe. 
Dodajte pufer za reakcijo, ki ste ga predhodno pripravili v 1-ml sterilno injekcijsko brizgo.
PHARMACEUTICAL FORM AND CONTENTS Kit for radiopharmaceutical preparation The box contains: - 1 vial of powder - 1 vial of buffer 
Komplet za pripravo radiofarmaka Škatla vsebuje: - 1 vialo praška - 1 vialo pufra
Figure 2: Radiolabelling procedure when using Galli Ad generator 
Slika 2: Postopek radioaktivnega označevanja pri uporabi generatorja Galli Ad
Pierce the Vial 1 septum with a 0.2 µm sterile vent filter in order to maintain atmospheric pressure within the vial during the radiolabelling process. 
Prebodite tesnilo viale 1 s sterilnim odzračevalnim filtrom 0,2 µm, da se med postopkom radioaktivnega označevanja v viali ohrani atmosferski tlak.
Assay the vial radioactivity using a suitable radioactivity calibration system and record the result. 
Izmerite radioaktivnost viale z ustreznim sistemom za umerjanje radioaktivnosti in rezultat zabeležite.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 40 micrograms 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 40 mikrogramov
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 08/12/2016 
Datum prve odobritve: 08/12/2016 10.
The injection of gallium (68Ga) edotreotide must be administered intravenously in order to avoid local extravasation resulting in inadvertent radiation to the patient and imaging artefacts. 
Injekcijo [68Ga]galij-edotreotida je treba dajati intravensko, da se izognemo lokalni ekstravazaciji, ki bi povzročila nehoteno obsevanje bolnika in artefakte pri slikanju.
Refer to the Summary of Product Characteristics of the particular generator for more information. 
Za več informacij glejte povzetek glavnih značilnosti zdravila posameznega generatorja.
In the retrospective paper of Schreiter et al. 2014, the intra-individual comparison in a subgroup of 20 patients showed that gallium (68Ga) edotreotide permitted to localise the primary tumour in 9/20 (45%) patients while indium (111In) pentetreotide did in 2/20 (10%). 
V retrospektivnem članku Schreiter et al. 2014 je primerjava posameznikov v podskupini 20 bolnikov pokazala, da je [68Ga]galij edotreotid omogočil lokalizacijo primarnega tumorja pri 9/20 (45 %) bolnikov, medtem ko je [111In]indij-pentetreotid to omogočil pri 2/20 bolnikih (10 %).
Recommended method for determining labelling efficiency of gallium (68Ga) edotreotide: 
Priporočena metoda za ugotavljanje učinkovitosti označevanja [68Ga]galij-edotreotida:
SomaKit TOC must not be used if there are visible signs of deterioration. 
Zdravila SomaKit TOC ne uporabljajte, če opazite vidne znake kvarjenja.
Radiolabelling of carrier molecules with gallium (68Ga) chloride is very sensitive to the presence of trace metal impurities. 
Radioaktivno označevanje nosilnih molekul z [68Ga]galijevim kloridom je zelo občutljivo na prisotnost sledov kovinskih nečistoč.
Only syringe and syringe needles able to minimise trace metal impurity levels (for example, non-metallic or coated with silicone needles - not supplied -) should be used. 
Uporabljati je treba samo injekcijske brizge in igle, ki lahko zmanjšajo raven sledi kovinskih nečistoč, na primer, nekovinske ali s silikonom prevlečene igle - te zdravilu niso priložene).
If the administration is considered necessary, breastfeeding should be interrupted for 8 hours and the expressed feeds discarded. 
Če je uporaba nujna, je treba dojenje po injiciranju prekiniti za 8 ur, izločeno mleko pa zavreči.
After administration of SomaKit TOC, you should: - avoid any close contact with young children and pregnant women for 8 hours after the injection - urinate frequently in order to eliminate the product from your body. 
Po uporabi zdravila SomaKit TOC: - se izogibajte tesnemu stiku z majhnimi otroci in nosečnicami še 8 ur po injiciranju;
However, lesions of GEP-NET not expressing sufficient density of somatostatin receptors cannot be visualised with gallium (68Ga) edotreotide. 
Vseeno lezij GEP NET, ki ne izražajo zadostne gostote somatostatinskih receptorjev, ni mogoče vizualizirati s [68Ga]galij-edotreotidom.
The solution should be visually inspected prior to use. 
Raztopino je treba pred uporabo pregledati.
Sodium hydroxide (E524) Water for injections 
Pufer mravljinčna kislina natrijev hidroksid (E524) voda za injekcije
In patients with Cushing syndrome, the normalisation of hypercortisolism should be considered before performing PET with SomaKit TOC. 
Pri bolnikih s Cushingovim sindromom je treba pred izvedbo PET z zdravilom SomaKit TOC razmisliti o normalizaciji hiperkortizolizma.
Gallium (68Ga) edotreotide detected 35/35 (100%) lesions vs 19/35=54% for indium (111In) pentetreotide SPECT/CT. 
Z [68Ga]galij-edotreotidom so odkrili 35/35 (100 %) lezij v primerjavi z 19/35 = 54 % pri SPECT/CT z [111In]indij-pentetreotidom.
The uptake in the liver and in the pituitary, thyroid and adrenal glands is lower. 
Privzem v jetrih in v hipofizi, ščitnici in nadledvičnih žlezah je nižji.
- Reaction buffer: the vial contains a clear, colourless solution. 
- Pufer za reakcijo: viala vsebuje bistro, brezbarvno raztopino.
Radiation safety - Product handling 
NAVODILA ZA PRIPRAVO RADIOFARMAKOV Varnost pri sevanju - ravnanje z zdravilom
What SomaKit TOC is and what it is used for 2. 
Kaj je zdravilo SomaKit TOC in za kaj ga uporabljamo 2.
Set the temperature of the shielded dry bath at 95°C and wait for the temperature to reach the set point and stabilize. 
Temperaturo zaščitene suhe kopeli nastavite na 95 °C in počakajte, da se stabilizira pri nastavljeni točki.
m. Assay the vial radioactivity using a suitable radioactivity calibration system and record the result. 
m. Izmerite radioaktivnost viale z ustreznim sistemom za umerjanje radioaktivnosti in rezultat zabeležite.
Somatostatin and its analogues are probably competing to bind to the same somatostatin receptors. 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Somatostatin in njegovi analogi verjetno tekmujejo za vezavo na iste somatostatinske receptorje.
Only clear solutions, free from visible particles should be used. 
Uporabiti smete le bistro raztopino brez vidnih delcev.
MARKETING AUTHORISATION HOLDER Advanced Accelerator Applications 20 rue Diesel 
Imetnik dovoljenja za promet Advanced Accelerator Applications 20 rue Diesel
In the study of Van Binnebeek et al. 2015 in 53 patients with metastatic GEP-NET [mostly GEP-NET (n=39) or NET of unknown origin (n=6)], the lesion-based detection rate of gallium (68Ga) edotreotide was 99.9% (1098/1099) versus 60% (660/1099) for indium (111In) pentetreotide based on the follow-up scans. 
študiji Van Binnebeek et al. 2015 je bila stopnja odkrivanja lezij pri 53 bolnikih z metastatskim GEPNET (večinoma GEP-NET (n=39) ali NET neznanega izvora (n=6)) z [68Ga]galij-edotreotidom 99,9 % (1098/1099) v primerjavi z 60-% (660/1099) stopnjo odkrivanja z [111In]indij-pentetreotidom na podlagi nadaljnjih slikanj.
Your nuclear medicine doctor will inform you if you need to take any other special precaution before or after using SomaKit TOC. 
Zdravnik nuklearne medicine vas bo obvestil, če boste pred ali po uporabi zdravila SomaKit TOC
At the end of the elution, first withdraw the needle from the vacuum vial in order to establish atmospheric pressure into Vial 1, then disconnect Vial 1 from the generator by removing the needle from the rubber septum. 
Po eluaciji najprej povlecite iglo iz vakuumske viale, da v viali 1 vzpostavite atmosferski tlak, in nato vialo 1 odklopite z generatorja, tako da iglo povlečete iz gumijastega tesnila.
As the effective dose is about 4.5 mSv when the maximal recommended activity of 200 MBq is administered, these adverse reactions are expected to occur with a low probability. 
Ker je učinkovit odmerek približno 4,5 mSv, kadar je največja priporočena aktivnost 200 MBq,
• Glass-fibre ITLC paper (e.g. Agilent ITLC SGI001) pre-cut to 1 cm x 12 cm strips Mobile phase: sodium Citrate 0.1 M (pH 5) in water 
• Papir iz steklenih vlaken ITLC (na primer Agilent ITLC SGI001), predhodno razrezan na trakove velikosti 1 x 12 cm Mobilna faza: natrijev citrat 0,1 M (pH 5) v vodi
The following authorised generators have shown to be compatible with SomaKit TOC: 
Z zdravilom SomaKit TOC so dokazano združljivi naslednji odobreni generatorji:
SomaKit TOC must not be used - if you are allergic to edotreotide or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na edotreotid ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
A prospective intra-individual comparison showed that gallium (68Ga) edotreotide is able to detect lesions better than indium (111In) pentetreotide. 
Prospektivna primerjava posameznikov je pokazala, da [68Ga]galij-edotreotid omogoča odkrivanje lezij bolje kot [111In]indij-pentetreotid.
In the study of Buchmann et al. 2007, conducted in 27 patients mostly with GEP-NET (59%) or NETs of unknown primary (30%), gallium (68Ga) edotreotide identified 279 lesions versus 157 lesions seen with indium (111In) pentetreotide. 
V študiji Buchmann et al. 2007, ki je bila izvedena s 27 bolniki, večinoma z GEP-NET (59 %) ali z NET neznanega izvora (30 %), so z [68Ga]galijedotreotidom odkrili 279 lezij v primerjavi s 157 lezijami, odkritimi z [111In]indij-pentetreotidom.
Driving and using machines It is considered unlikely that SomaKit TOC will affect your ability to drive or to use machines. 
Ni verjetno, da bo imelo zdravilo SomaKit TOC vpliv na sposobnost vožnje ali upravljanja strojev.
What you need to know before SomaKit TOC is used 3. 
Kaj morate vedeti, preden boste uporabili zdravilo SomaKit TOC 3.
Thin layer chromatography (ITLC2, see details below) 
Tankoplastna kromatografija (ITLC2, glejte podrobnosti spodaj)
The activity of gallium (68Ga) edotreotide has to be measured with an activimeter immediately prior to injection. 
Aktivnost [68Ga]galij-edotreotida je treba tik pred injiciranjem izmeriti z merilnikom aktivnosti.
About 50 minutes after intravenous administration, gallium (68Ga) edotreotide accumulation shows plateauing in all organs. 
Približno 50 minut po intravenskem dajanju akumulacija [68Ga]galij-edotreotida v vseh organih doseže plato.
After radiolabelling, the solution obtained also contains hydrochloric acid. 
Po radioaktivnem označevanju dobljena raztopina vsebuje tudi klorovodikovo kislino.
Before it can be used, the powder in the vial is mixed with a radioactive substance called gallium (68Ga) chloride to make gallium (68Ga) edotreotide (this procedure is called radiolabelling). 
Pred uporabo se prašek v viali zmeša z radioaktivno snovjo, imenovano [68Ga]galijev klorid, s čimer se pridobi snov, imenovana [68Ga]galij-edotreotid (ta postopek se imenuje radioaktivno označevanje).
Radioactive waste must be disposed of in accordance with relevant national regulations. 
Radioaktivne odpadke je treba zavreči skladno z nacionalnimi predpisi.
Thin layer chromatography (ITLC1, see details below) 
Tankoplastna kromatografija (ITLC1, glejte podrobnosti spodaj)
• Developing tank 
• Razvijalna posoda
At the end of the elution, disconnect the generator from the Vial 1 withdrawing the needle from the rubber septum and immediately add the reaction buffer previously dosed in the 1 ml sterile syringe. 
Po eluaciji odklopite generator z viale 1, tako da iglo povlečete iz gumijastega tesnila, in takoj dodajte pufer za reakcijo, ki ste ga predhodno pripravili v 1-ml sterilno injekcijsko brizgo.
Test 
Preizkus
- A glass vial with yellow flip-off cap containing a clear and colourless solution. 
- Stekleno vialo z rumeno zaporko (tipa »flip-off«), ki vsebuje bistro in brezbarvno raztopino.
Due to the acidic pH of the radiolabelled gallium (68Ga) edotreotide solution, accidental extravasation may cause local irritation. 
Zaradi kislega pH radioaktivno označene raztopine z [68Ga]galij-edotreotidom lahko nenamerna ekstravazacija povzroči lokalno draženje.
Flip off cap from the Vial 2 (Reaction buffer) and swab the top of the vial closure with an appropriate antiseptic to disinfect the surface, and then allow the stopper to dry. 
Odprite zaporko (tipa »flip-off«) na viali 2 (pufra za reakcijo) in obrišite vrh viale z ustreznim antiseptičnim sredstvom za razkuževanje površine, nato pa pustite, da se zamašek posuši.
- if you have others medical conditions, such as high level of cortisol in the body (Cushing syndrome), inflammation, thyroid disease, other type of tumour (of pituitary gland, lung, brain, breast, immune system, thyroid, adrenal gland or others) or disease of spleen that may affect the interpretation of the images; - if you have been taking other medicines, such as somatostatin analogues and glucocorticoids, which may interact with SomaKit TOC; - if you are pregnant or believe you may be pregnant; - If you are breast-feeding. 
- če imate kakršna koli druga zdravstvena stanja, kot so visoka raven kortizola v telesu (Cushingov sindrom), vnetje, bolezen ščitnice, druge vrste tumorja (hipofize, pljuč, možganov, dojk, imunskega sistema, ščitnice, nadledvične žleze ali drugega) ali bolezen vranice, ki lahko vplivajo na interpretacijo slik;
Renal/Hepatic impairment The pharmacokinetics in patients with renal or hepatic impairment has not been characterized. 
Ledvična in jetrna okvara Farmakokinetičnih značilnosti pri bolnikih z ledvično ali jetrno okvaro niso preučevali.
Mechanism of action Gallium (68Ga) edotreotide binds to somatostatin receptors. 
Mehanizem delovanja Galijev (68Ga) edotreotid se veže na somatostatinske receptorje.
• Glass-fibre ITLC paper (e.g. Agilent ITLC SGI001) pre-cut to 1 cm x 12 cm strips 
• Papir iz steklenih vlaken ITLC (na primer Agilent ITLC SGI001), predhodno razrezan na trakove velikosti 1 x 12 cm
Interpretation of gallium (68Ga) edotreotide images and limitations of use PET images with gallium (68Ga) edotreotide reflect the presence of somatostatin receptors in the tissues. 
Interpretacija slik [68Ga]galij-edotreotida in omejitve uporabe Slike PET [68Ga]galij-edotreotida odražajo prisotnost somatostatinskih receptorjev v tkivih.
PET images with gallium (68Ga) edotreotide should be interpreted visually, and semiquantitative measurement of gallium (68Ga) edotreotide uptake should not be used for clinical interpretation of images. 
Slike PET [68Ga]galij-edotreotida je treba interpretirati vizualno, semikvantitativnega merjenja privzema [68Ga]galij-edotreotida pa ne smemo uporabljati za klinično interpretacijo slik.
After radiolabelling 
po radioaktivnem označevanju
What SomaKit TOC is and what it is used for 
Kaj je zdravilo SomaKit TOC in za kaj ga uporabljamo
Other medicines and SomaKit TOC 
Druga zdravila in zdravilo SomaKit TOC
In GEP-NET, a more intense gallium (68Ga) edotreotide uptake than normal background is a consistent finding. 
V GEP-NET je dosledno ugotovljen intenzivnejši privzem [68Ga]galij-edotreotida kot pri običajnem ozadju.
In case of Cushing syndrome, a long-term exposure to endogenous hypercortisolism may down regulate somatostatin receptor expression and negatively influence the results of somatostatin receptor imaging with gallium (68Ga) edotreotide. 
V primeru Cushingovega sindroma lahko dolgoročna izpostavljenost endogenemu hiperkortizolizmu negativno regulira izražanje somatostatinskih receptorjev in negativno vpliva na rezultate slikanja somatostatinskih receptorjev z [68Ga]galij-edotreotidom.
One vial of powder contains 40 µg of edotreotide. 
Ena viala praška vsebuje 40 µg edotreotida.
Organ uptake The organ with the highest physiological uptake of gallium (68Ga) edotreotide is the spleen, followed by the kidneys. 
Privzem v organih Organ z najvišjim fiziološkim privzemom [68Ga]galij-edotreotida je vranica, sledijo pa ledvice.
Close contact with infants and pregnant women should be restricted during the first 8 hours after administration. 
V 8 urah po dajanju je treba omejiti tesne stike z dojenčki in nosečnicami.
(70%) and discrepancies in 14 patients (30%) presenting 9 with progressive disease and 5 with remission. 
PET in CT z [68Ga]galij-edotreotidom sta dala skladne rezultate pri 32 bolnikih (70 %) in neskladnosti pri 14 bolnikih (30 %), pri čemer jih je 9 bilo s progresivno boleznijo in 5 z remisijo.
In the study by Gabriel et al. 2009 pre-PRRT gallium (68Ga) edotreotide was compared with CT or MRI using the Response Evaluation Criteria in Solid Tumors (RECIST). 
2009 so primerjali uporabo [68Ga]galij-edotreotida pred PRRT s CT ali MRI po merilih za vrednotenje odziva pri solidnih tumorjih (merila RECIST).
The patient dose should be measured by a suitable radioactivity calibration system immediately prior to patient administration. 
Odmerek za bolnika je treba tik pred dajanjem izmeriti z ustreznim sistemom za umerjanje radioaktivnosti.
With a low dead space 1 ml sterile syringe carefully withdraw 100 µl and keep the reaction buffer in syringe for step “g”. 
S sterilno 1-ml injekcijsko brizgo z majhnim volumnom mrtvega prostora previdno povlecite 100 µl in ohranite pufer za reakcijo v injekcijski brizgi za korak »g«.
The organs with high physiological uptake of gallium (68Ga) edotreotide include spleen, kidneys, liver, pituitary gland, thyroid gland and adrenals. 
Organi z visokim fiziološkim privzemom [68Ga]galij-edotreotida vključujejo vranico, ledvice, jetra, hipofizo, ščitnico in nadledvične žleze.
METHOD AND ROUTE(S) OF ADMINISTRATION To be radiolabelled with the reaction buffer and a solution of Gallium-68 (68Ga) in HCl provided by a germanium (68Ge)/gallium (68Ga) generator. 
Za radioaktivno označevanje s pufrom za reakcijo in raztopino galija-68 (68 Ga) v HCl iz generatorja germanija (68Ge)/galija (68Ga).
The quality controls should be performed under a shielded screen for radioprotection purposes. 
Nadzor kakovosti je treba, zaradi zaščite pred sevanjem, opraviti pod zaščitnim zaslonom.
Before administering radiopharmaceuticals to a mother who is breastfeeding, consideration should be given to the possibility of delaying the administration of radionuclide until the mother has ceased breastfeeding, and to what is the most appropriate choice of radiopharmaceuticals, bearing in mind the secretion of activity in breast milk. 
dokler mati ne neha dojiti, in o najustreznejši izbiri radiofarmakov, pri čemer je treba upoštevati izločanje aktivnosti sevanja v materino mleko.
Data supporting efficacy of gallium (68Ga) edotreotide for predicting and monitoring of therapeutic response to peptide receptor radionuclide therapy (PRRT) in histologically confirmed metastatic NET are limited (see section 5.1). 
Podatki, ki podpirajo učinkovitost [68Ga]galij-edotreotida pri predvidevanju in spremljanju terapevtskega odziva na radionuklidno terapijo s peptidnimi receptorji (PRRT, peptide receptor radionuclide therapy) v histološko potrjenem metastatskem NET, so omejeni (glejte poglavje 5.1).
Each 40 microgram vial contains an excess of product. 
Ena viala s 40 mikrogrami vsebuje čezmerno količino zdravila.
In vivo, semiquantitative correlation was not assessed between gallium (68Ga) edotreotide uptake in tumours and the density of SSTR in histopathological samples neither in GEP-NET patients nor in normal organs. 
Semikvantitativna korelacija med privzemom [68Ga]galij-edotreotida v tumorjih in gostoto SSTR v histopatoloških vzorcih ni bila ocenjena in vivo, niti pri bolnikih z GEP-NET niti pri normalnih organih.
pH-indicator strips 
Indikatorski trakovi za pH
EXP: ________ Time/Date 
Uporabno do: ________ ura/datum
Gallium (68Ga) edotreotide has no or negligible influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Galijev (68Ga) edotreotid nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Thus, in patients with GEP-NET and Cushing syndrome, normalisation of hypercortisolism should be suggested before performing PET with gallium (68Ga) 
Pri bolnikih z GEP NET in Cushingovim sindromom je treba torej pred izvedbo PET z [68Ga]galij-edotreotidom predlagati normalizacijo hiperkortizolizma.
After radiolabelling, the solution obtained also contains, as excipient, hydrochloric acid from the generator eluate. 
Po radioaktivnem označevanju dobljena raztopino kot pomožno snov vsebuje tudi klorovodikovo kislino iz eluata iz generatorja.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION SomaKit TOC 
IME ZDRAVILA IN POT(I) UPORABE SomaKit TOC
A long-term exposure to endogenous hypercortisolism may down-regulate somatostatin receptor expression and negatively influence the results of somatostatin receptor imaging with gallium (68Ga) 
Dolgoročna izpostavljenost endogenemu hiperkortizolizmu lahko negativno regulira izražanje somatostatinskih receptorjev in negativno vpliva na rezultate slikanja somatostatinskih receptorjev z [68Ga]galij-edotreotidom.
Flip off cap from the vial of powder and swab the top of the vial closure with an appropriate antiseptic to disinfect the surface, and then allow the stopper to dry. 
Odprite zaporko (tipa »flip-off«) na viali praška in obrišite vrh viale z ustreznim antiseptičnim sredstvom za razkuževanje površine, nato pa pustite, da se zamašek posuši.
The safety and efficacy of gallium (68Ga) edotreotide has not been established in paediatric populations, where the effective dose might be different than in adults. 
Varnost in učinkovitost [68Ga]galij-edotreotida pri pediatrični populaciji nista bili dokazani, učinkoviti odmerek pa je lahko drugačen kot pri odraslih.
With a low dead space 1 ml sterile syringe carefully withdraw 0.5 ml reaction buffer, and keep the reaction buffer in syringe for step “i”. 
S sterilno 1-ml injekcijsko brizgo z majhnim volumnom mrtvega prostora previdno povlecite 0,5 ml pufra za reakcijo in ohranite pufer za reakcijo v injekcijski brizgi za korak »i«.